McGill Colin M, Brown Timothy J, Cheng Yuan-Yin, Fisher Lindsey N, Shanmugavelandy Sriram S, Gustafson Sally J, Dunlap Kriya L, Lila Mary Ann, Kester Mark, Toran Paul T, Claxton David F, Barth Brian M
Department of Chemistry, University of Alaska-Anchorage, Anchorage, AK 99508 USA.
Department of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033 USA.
Int J Biopharm Sci. 2018 Jan;1(1). Epub 2018 Jan 2.
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with high incidence in the aging population. In addition, AML is one of the more common pediatric malignancies. Unfortunately, both of these patient groups are quite sensitive to chemotherapy toxicities. Investigation of blueberries specifically as an anti-AML agent has been limited, despite being a prominent natural product with no reported toxicity. In this study, blueberry extracts are reported for the first time to exert a dietary therapeutic effect in animal models of AML. Furthermore, studies revealed that blueberry extracts exerted anti-AML efficacy against myeloid leukemia cell lines as well as against primary AML, and specifically provoked Erk and Akt regulation within the leukemia stem cell subpopulation. This study provides evidence that blueberries may be unique sources for anti-AML biopharmaceutical compound discovery, further warranting fractionation of this natural product. More so, blueberries themselves may provide an intriguing dietary option to enhance the anti-AML efficacy of traditional therapy for subsets of patients that otherwise may not tolerate rigorous combinations of therapeutics.
急性髓系白血病（AML）是一种侵袭性血液恶性肿瘤，在老年人群中发病率较高。此外，AML是较为常见的儿童恶性肿瘤之一。不幸的是，这两类患者群体对化疗毒性都相当敏感。尽管蓝莓是一种未报道有毒性的著名天然产物，但专门作为抗AML药物的研究却很有限。在本研究中，首次报道了蓝莓提取物在AML动物模型中发挥饮食治疗作用。此外，研究表明蓝莓提取物对髓系白血病细胞系以及原发性AML均具有抗AML疗效，并且特别能在白血病干细胞亚群中引发Erk和Akt调节。本研究提供了证据，表明蓝莓可能是发现抗AML生物制药化合物的独特来源，进一步证明了对这种天然产物进行分离的必要性。更重要的是，对于那些可能无法耐受严格治疗组合的部分患者，蓝莓本身可能提供一种有趣的饮食选择，以增强传统疗法的抗AML疗效。
